The data presented in these tables were obtained from proxy statements and annual reports of biotechnology companies that were filed with the U.S. Securities and Exchange Commission (SEC). Unless otherwise noted with symbols, companies had a fiscal year-end of Dec. 29, 2006. Numbered footnotes containing important details appear following this section. IMPORTANT NOTE: The sample size of companies shrinks to 197 in the case of this position because many companies have no such position listed

The data presented in these tables were obtained from proxy statements and annual reports of biotechnology companies that were filed with the U.S. Securities and Exchange Commission (SEC). Unless otherwise noted with symbols, companies had a fiscal year-end of Dec. 29, 2006. Numbered footnotes containing important details appear following this section. IMPORTANT NOTE: The sample size of companies shrinks to 197 in the case of this position because many companies have no such position listed

The data presented in these tables were obtained from proxy statements and annual reports of biotechnology companies that were filed with the U.S. Securities and Exchange Commission (SEC). Unless otherwise noted with symbols, companies had a fiscal year-end of Dec. 29, 2006. Numbered footnotes containing important details appear following this section. IMPORTANT NOTE: The sample size of companies shrinks to 94 in the case of this position because many companies have no such position listed

The data presented in these tables were obtained from proxy statements and annual reports of biotechnology companies that were filed with the U.S. Securities and Exchange Commission (SEC). Unless otherwise noted with symbols, companies had a fiscal year-end of Dec. 29, 2006. Numbered footnotes containing important details appear following this section. IMPORTANT NOTE: The sample size of companies shrinks to 259 in the case of CFOs because many companies have no CFO listed among the top wage

The data presented in these tables were obtained from proxy statements and annual reports of biotechnology companies that were filed with the U.S. Securities and Exchange Commission (SEC). Unless otherwise noted with symbols, companies had a fiscal year-end of Dec. 29, 2006. Numbered footnotes containing important details appear following this section. IMPORTANT NOTE: The CEO listed for 273 companies is the individual who held that title for the majority of the fiscal year reported. In those

For Executives Who Received A Full Year of Salary Total: $524,500

For Executives Who Received A Full Year of Salary Total: $471,500

For R&D Executives Who Received A Full Year of Salary Total: $564,000

For COOs Who Received A Full Year of Salary Total: $513,000

For CFOs Who Received A Full Year of Salary Total: $461,000

For CEOs Who Received A Full Year of Salary Total: $1,038,000

For CEOs Who Received A Full Year of Salary Total: $555,000

Number of companies: 275 Total number of employees at the 275 companies: 122,821 Average number of employees: 458 Median number of employees: 122 Total market capitalization of the 275 companies on Dec. 30, 2006: $376.2 billion Average market capitalization per company on Dec. 30, 2006: $1.4 billion Median market capitalization per company on Dec. 30, 2006: $180.6 million Smallest market capitalization on Dec. 30, 2006: $1.9 million (Macrochem Corp.) Largest market capitalization on Dec

Managing Editor It's been a year of upheaval and uncertainty on many fronts for Amgen Inc., layoffs and falling share prices among them. But the biggest of the biotechnology companies seems to do everything big including the salaries of its top executives. Amgen continued to dominate the salary rankings in BioWorld's 2008 Executive Compensation Report, with its CEO, CFO, and COO all ranking No. 1 in compensation in their categories. But with compensation packages weighting more heavily toward

For The Public Biotechnology Companies In BioWorld's Survey Number of companies: 269 Total number of employees at the 269 companies: 114,901 Average number of employees: 430 Median number of employees: 114 Total Market Capitalization of the 269 companies on Dec. 30, 2005: $352.1 billion Average Market Capitalization per company on Dec. 30, 2005: $1.4 billion Median Market Capitalization per company on Dec. 30, 2005: $173.4 million Smallest Market Capitalization on Dec. 30, 2005: $1.8

Using the 269 proxy statements, we have gathered data on the compensation of executives responsible for legal affairs in the industry. The sample size of companies shrinks to 79 in the case of this position because many companies have no such position listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number companies have no such position at all. The

Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Accentia Biopharmaceuticals (a) Samuel S. Duffey 272 0 272 0 0 272 0 541 Affymetrix Inc. Barbara A. Caulfield 374 0 374 83 5,571 6,029 0 3,253 Alexion Pharmaceuticals Inc. Thomas I.H. Dubin 235 89 324 2 0 327 104 0 Alkermes